CN117279644A - 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 - Google Patents

用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 Download PDF

Info

Publication number
CN117279644A
CN117279644A CN202280018587.1A CN202280018587A CN117279644A CN 117279644 A CN117279644 A CN 117279644A CN 202280018587 A CN202280018587 A CN 202280018587A CN 117279644 A CN117279644 A CN 117279644A
Authority
CN
China
Prior art keywords
dihydro
oxadiazin
trifluoromethyl
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280018587.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·兰格
S·考尔福斯
C·C·科皮茨
H·格鲁利希
X·吴
M·迈耶森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Original Assignee
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Dana Farber Cancer Institute Inc, Broad Institute filed Critical Bayer AG
Publication of CN117279644A publication Critical patent/CN117279644A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280018587.1A 2021-03-03 2022-03-02 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 Pending CN117279644A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156193P 2021-03-03 2021-03-03
US63/156,193 2021-03-03
PCT/EP2022/055211 WO2022184748A1 (en) 2021-03-03 2022-03-02 Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma

Publications (1)

Publication Number Publication Date
CN117279644A true CN117279644A (zh) 2023-12-22

Family

ID=80780814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280018587.1A Pending CN117279644A (zh) 2021-03-03 2022-03-02 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮

Country Status (7)

Country Link
US (1) US20230405015A1 (enExample)
EP (1) EP4301371A1 (enExample)
JP (1) JP2024508171A (enExample)
CN (1) CN117279644A (enExample)
CA (1) CA3212314A1 (enExample)
TW (1) TW202302113A (enExample)
WO (1) WO2022184748A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037063A2 (en) * 1998-12-22 2000-06-29 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
CN106573931A (zh) * 2014-06-18 2017-04-19 拜耳医药股份有限公司 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3，4‑二氢吡啶并[2，3‑b]吡嗪酮

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6445573B2 (ja) * 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディＳａｒｔａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
WO2017027854A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
TW201733591A (zh) * 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
US11142522B2 (en) * 2017-02-03 2021-10-12 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037063A2 (en) * 1998-12-22 2000-06-29 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
CN106573931A (zh) * 2014-06-18 2017-04-19 拜耳医药股份有限公司 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3，4‑二氢吡啶并[2，3‑b]吡嗪酮

Also Published As

Publication number Publication date
EP4301371A1 (en) 2024-01-10
JP2024508171A (ja) 2024-02-22
TW202302113A (zh) 2023-01-16
WO2022184748A1 (en) 2022-09-09
US20230405015A1 (en) 2023-12-21
CA3212314A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US11964953B2 (en) Substituted aminothiazoles as DGKzeta inhibitors for immune activation
US11787797B2 (en) 4,5-annulated 1,2,4-triazolones
CN116323623B (zh) 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
US12258323B2 (en) Dihydrooxadiazinones
US20230064809A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4602049A1 (en) Sos1 inhibitors
US10179123B2 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
JP2018514539A (ja) Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ
US20240156999A1 (en) Multimeric chelator compounds for use in targeted radiotherapy
EP3219329A1 (en) Combinations of copanlisib
US20210317128A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2019197269A1 (en) Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210369724A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
HK40105245A (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
EP3195865A1 (de) Kombinationen von irak4 inhibitoren und btk inhibitoren
WO2020048826A1 (en) 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2021260443A1 (en) Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105245

Country of ref document: HK